Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study

Participants needed: 81
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: OriCell Therapeutics Co., Ltd.Updated: Aug 2, 2024Locations: 1
Eligibility criteria

Not listed

Read more
Status: Recruiting

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

An open label, dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of OriCAR-017 in R/RMM

Participants needed: 83
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: OriCell Therapeutics Co., Ltd.Updated: May 31, 2024Locations: 5
Eligibility criteria

Diagnosis of R/RMM according to the IMWG criteria; [+7]

Smoldering myeloma (asymptomatic) [+13]

Read more
Status: Recruiting

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).

Participants needed: 105
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: OriCell Therapeutics Co., Ltd.Updated: Apr 3, 2024Locations: 7
Eligibility criteria

Confirmed pathologic or radiologic diagnosis of HCC ; [+7]

Central nervous system metastatic disease, leptomeningeal disease, or metastatic... [+8]

Read more